Key result
Eptifibatide and other GPIIb/IIIa inhibitors linked to severe thrombocytopenia during PCI for ACS.
Why the study?
With the growing use of glycoprotein IIb/IIIa inhibitors in ACS patients undergoing PCI, an increase in related adverse events including severe thrombocytopenia is being reported.
Does eptifibatide cause severe thrombocytopenia in patients with ACS undergoing PCI?
Does eptifibatide cause severe thrombocytopenia in patients with ACS undergoing PCI?
Highlights the risk of severe thrombocytopenia as an adverse event associated with eptifibatide use in ACS patients undergoing PCI.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to thrombocytopenia risk with eptifibatide in ACS PCI; leaves open causal confirmation in randomized data.
Glycoprotein (GP) IIb/IIIa are now being widely used in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). With the growing use of these medications, there is an increase in adverse events related to them being reported in the literature, including severe thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Sallam et al. (2022) studied this question. Eptifibatide and other glycoprotein IIb/IIIa inhibitors are associated with severe thrombocytopenia in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: